[Apolipoprotein C-III in nephrology].
Apolipoprotein C-III is synthesized by the liver and the small intestine. It inhibits the actions of lipoprotein lipase and hepatic triglyceride lipase. An increase of plasma apolipoprotein C-III levels has been found in patients with renal failure, in those under haemodialysis and in renal transplant recipients. The consequences of this increase correlate with the hypertriglyceridaemia observed in these patients. The responsibility of hormonal or non-hormonal factors that modulate the metabolism of apolipoprotein C-III is discussed in order to help in the understanding of the physiopathological mechanisms of lipid disorders in these renal diseases.
Massy
Z A
ZA
INSERM U90, Paris.
Lacour
B
B
D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000097:blood* / Q000737:chemistry; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008049:Lipase / Q000378:metabolism; D008071:Lipoprotein Lipase / Q000378:metabolism; D008297:Male; D009404:Nephrotic Syndrome / Q000097:blood*; D014280:Triglycerides / Q000378:metabolism
D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D014280:Triglycerides; D008049:Lipase; D008071:Lipoprotein Lipase